SaCas9 All-in-One Editor (AAV)

SaCas9 nuclease in single AAV with customizable guide RNA. Wild-type Staphylococcus aureus Cas9 is the established standard for compact CRISPR-AAV systems with KKH-enhanced PAM recognition (NNGRRT). Validated performance across diverse cell types and in vivo applications^1,2.

Deliverables

• Titer:  1e13 VG/mL or higher
• Full Capsid Ratio: 0.85 or higher
  
• Delivery: 18–21 days

Application

Compatible with in vivo gene editing in the CNS, liver, muscle, and other tissues accessible by AAV. Well-suited for knockout studies, disease modeling, and therapeutic development where single-vector delivery is essential. Choose promoter and capsid based on target tissue and expression requirements.

• CMV (Cytomegalovirus): Strong, ubiquitous expression across most cell types; highest initial transgene levels
• EFS (EF1α Short): Compact promoter with stable, constitutive expression; reduced silencing versus viral promoters
• hPGK (Human Phosphoglycerate Kinase): Moderate, stable expression; lower immunogenicity for in vivo applications
• hSyn (Human Synapsin): Neuron-specific expression for CNS-targeted applications

Specifications

Single stranded AAV produced in 293T cells and purified through two (2) rounds of CsCl ultracentrifugation and stored in 0.001% F-68 in DPBS with additional 150 mM NaCl. Ships on dry ice overnight.

References

1. Ran et al. (2015) Nature 520:186-191 (https://doi.org/10.1038/nature14299) In vivo genome editing using Staphylococcus aureus Cas9
2. Kleinstiver et al. (2015) Nature Biotechnology 33:1293-1298 (https://doi.org/10.1038/nbt.3404) Engineered CRISPR-Cas9 nucleases with altered PAM specificities (KKH variant)